Fosaprepitant (INN; trade names Emend for Injection, Ivemend) is an anti-emetic drug, administered intravenously. It is a prodrug of aprepitant. It was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008 . and by the European Medicines Agency (EMA) on January 11 of the same year.
| Property | Value |
|---|
| dbpprop:abstract
|
- Fosaprepitant (INN; trade names Emend for Injection, Ivemend) is an anti-emetic drug, administered intravenously. It is a prodrug of aprepitant. It was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008 . and by the European Medicines Agency (EMA) on January 11 of the same year.
|
| rdfs:comment
|
- Fosaprepitant (INN; trade names Emend for Injection, Ivemend) is an anti-emetic drug, administered intravenously. It is a prodrug of aprepitant. It was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008 . and by the European Medicines Agency (EMA) on January 11 of the same year.
|
| rdfs:label
| |
| owl:sameAs
| |
| skos:subject
| |
| foaf:page
| |
| is dbpprop:redirect
of | |
![[RDF Data]](/statics/sw-cube.png)
